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Purpose. To evaluate the early response to intravitreal ranibizumab (IVR) in two diﬀerent phenotypes of age-related macular
degenerations (AMD):typicalneovascularAMD (tAMD) and polypoidalchoroidalvasculopathy(PCV).Methods.Sixtyey esfr om
60 patients (tAMD 28, PCV 32 eyes) were recruited. Three consecutive IVR treatments (0.5mg) were performed every month.
Changein the best-corrected visual acuity (BCVA) and central retinal thickness(CRT) wasthen compared between the tAMD and
PCV groups. Results. The mean BCVA logMAR was signiﬁcantly improved at month 1 and month 3 after the initial IVR in the
tAMD group, but there was no change in the PCV group. Both phenotypes showed signiﬁcant improvements in the CRT during
the 3 months after the initial IVR. There were no signiﬁcant diﬀerences in the improvements of the CRT in the tAMD versus
the PCV group. In the stepwise analysis, a worse pretreatment BCVA and tAMD lesions were signiﬁcantly beneﬁcial for a greater
improvement of BCVA at 3 months after the initial IVR. Conclusions. The phenotype of tAMD showed a signiﬁcantly better early
response to IVR than PCV in terms of BCVA improvement.
1.Introduction
The intravitreal injection of ranibizumab (IVR) is currently
the treatment of choice for subfoveal choroidal neovascu-
larization (CNV) due to age-related macular degeneration
(AMD), a leading cause of central visual loss in the elderly in
industrialized countries [1, 2]. Several studies from Western
countries have reported a signiﬁcant improvement in vision
at 3 months with monthly IVRs [3, 4]. However, the eﬃcacy
of IVR has not been investigated well for exudative AMD in
the Japanese population. A recent report described a good
response to intravitreous bevacizumab in Japanese AMD
patients with classic CNV lesions, but there was limited eﬃ-
cacy in those with occult CNV lesion [5]. We hypothesized
that those results might be attributed to the proportion of
AMD subtypes in the Japanese population, which includes
polypoidal choroidal vasculopathy (PCV) as the major phe-
notype of exudative AMD [6], and the eﬀects of antivascular
endothelial growth factor (VEGF) therapy for PCV may dif-
fer from those for typical neovascular AMD (tAMD). Recent
publicationshavereportedthattheeﬀectsofanti-VEGFther-
apy were limited in PCV [7–9]. However, to our knowledge,
no comparative studies have been published on the eﬀective-
nessofIVRassociatedwiththediﬀerentphenotypesofAMD.
In this study, we ﬁrst performed a comparative assess-
ment to determine whether the early responses to IVR were
diﬀerent between tAMD and PCV. In addition, a multiple
regression analysis was performed to determine if the
AMD phenotype (tAMD or PCV) may inﬂuence the visual
outcomes of IVR independently, with several pretreatment
factors which might aﬀect the outcomes of the IVR.
2.Subjectsand Methods
All cases in this study were Japanese individuals recruited
from the Department of Ophthalmology at the Kobe Uni-
versity Hospital in Japan. Written informed consent was
obtained from all subjects.
Sixty eyes from 60 patients (tAMD 28, PCV 32 eyes)
were recruited. All patients received detailed ophthalmic2 Journal of Ophthalmology
examinations, includingbest-corrected visual acuity (BCVA)
measurements, slit lamp biomicroscopy of their fundi, color
fundus photography, optical coherence tomography, ﬂuo-
rescein angiography (FA), indocyanine green angiography
(ICG),and opticalcoherence tomography (OCT).A detailed
questionnaire on the patient’s basic characteristics including
age, body weight and height, the presence or absence of
hypertension and diabetic mellitus, and any history of
smoking (current, past, or nonsmoker) was also obtained.
The diﬀerential diagnoses of tAMD and PCV were made in
accordance with previous reports [10–12]. Brieﬂy, the tAMD
group included only wet tAMD with clear images of the vas-
cular CNV networks on ICG. The PCV cases in the present
study showed subretinal reddish-orange protrusions corre-
sponding with the choroidal origin of the polypoidal lesions,
typically with the vascular networks in the posterior poles
on ICG [13, 14]. Patients with past histories of retinal vessel
occlusion, uveitis, rhegmatogenous retinal detachment, or
glaucoma were excluded. Patients who received previous
photodynamic therapy (PDT) within 3 months or any other
treatments within 6 months for AMD were also excluded.
All patients received 3 consecutive IVRs every month
as previously described and followed up monthly for 3–
12 months from the initial IVR [3, 4]. Additional IVR was
performed as needed, namely, when sustained or recurrent
serous retinal detachment, macular edema, or hemorrhage
was recognized.
For statistical analysis, ﬁrst, we compared the gender,
age, BCVA, greatest linear dimension (GLD), central retinal
thickness (CRT), history of smoking, presence of hyperten-
sion and diabetes mellitus, and body mass index (BMI) at
baseline between the tAMD and PCV groups. Changes in the
BCVA and CRT were then compared until 3 months after
the initial IVR. Since the early response to IVR is known
to be achieved within 3 months using monthly IVRs, we
focused on the comparison between the eﬀects of IVR in
tAMD and PCV during this term. To evaluate the factors
useful for predicting the BCVA at 3 months after the initial
IVR, stepwise multiple regression analyses with backward
elimination methods were performed using explanatory
variablesincludedgender,age,baseline BCVA,baseline GLD,
baseline CRT, history of smoking, presence of hypertension
and diabetes mellitus, BMI, and lesion phenotype (tAMD or
PCV). The visual acuitieswere determined using a Landolt C
chartandwereconvertedtologarithmoftheminimumangle
of resolution (logMAR) values for calculation.
The stepwise multiple regression analysis was performed
by IBM SPSS Statistics 19 software (IBM Inc., Armonk, NY,
USA), and all other statistical analyses were performed by
MedCalc v.11.3 software (MedCalc Software bvba, Mariak-
erke, Belgium). Except for the multivariate analysis, a two-
tailed t-test or Wilcoxon’s signed-rank test was performed
to compare any two groups. P values of .05 or less were
considered to be statistically signiﬁcant.
3.Results
The data summary of each phenotype (tAMD and PCV) is
shown in Table 1. Patients with tAMD showed signiﬁcantly
































Figure 1: Changes in the best-corrected visual acuity (BCVA) for
tAMD and PCV patients after intravitreal ranibizumab. The BCVA
was determined using the Landolt C chart and was presented as
decimalvisualacuities.Diamondswithdashedlines:tAMD;squares
with solid lines: PCV. Values represent means ± SEM.
better visual outcomes than patients with PCV. In the time
course analysis, the BCVA at 1 month and 3 months after
the initial IVR was signiﬁcantly improved as compared with
the baseline BCVA in the tAMD group (P = .0084 and
P = .0008, resp., Wilcoxon’s signed-rank test). In contrast,
in the PCV group, the BCVA at 1 month and 3 months
tended to improve over the baseline BCVA, but there was no
statistical signiﬁcance (P = .38andP = .55,resp.,Wilcoxon’s
signed-rank test) (Figure 1 and Table 2). The improvement
of the BCVA at 3 months after the initial IVR from baseline
was signiﬁcantly greater in the tAMD patients than in the
PCV patients (P = .0045; Mann-Whitney U test). In the
52 eyes (tAMD 27, PCV 25 eyes) which were followed-up
for 12 months after the ﬁrst IVR, the BCVA was kept better
than baseline (−0.14 and −0.11 at 6 months and 12 months,
resp.) in the tAMD group although the signiﬁcance was
reduced (P = .018 and 0.064 at 6 months and 12 months,
resp.). In the PCV group, no signiﬁcant improvement of
BCVA was found up to 12 months after the ﬁrst IVR (−0.03,
P = .35 and −0.0047, P = .90 at 6 months and 12 months,
resp.). In addition, BCVA in the group having pretreatment
subretinal hemorrhage within 1 disc area was signiﬁcantly
improved 3 months after the ﬁrst IVR whereas what in the
group having subretinal hemorrhage more than 1 disc area
was not improved at the same time period (Table 3). The
time course of the mean CRT in the tAMD and PCV groups
is shown in Figure 2. Both phenotypes showed signiﬁcant
improvements in the CRT during the 3 months after the
initial IVR (Table 2). There were no signiﬁcant diﬀerences in
the improvements of the CRT in the tAMD versus the PCV
group.
The results of the stepwise multiple regression analyses
are shown in Table 4. Two factors were signiﬁcantly associ-
ated with the change of BCVA at 3 months after the initial
IVR, which were actually more improved in (i) patients with
aw o r s ep r e t r e a t m e n tB C V A( P = .026) and (ii) tAMD
lesions (P = .013).
As complications, slight lens damage was found in one
case after the second IVR. No other ocular or systemicJournal of Ophthalmology 3
Table 1: Data summary of the participants stratiﬁed by AMD phenotype.
PCV tAMD total P value
(n = 32) (n = 28) (n = 60)
Right eyes (%) 15 (47%) 12 (43%) 27 (45%) .96†
Males (%) 25 (78%) 23 (82%) 48 (80%) .95†
Mean age (±SD)Years 74.6 (±9.0) 74.4 (±9.2) 74.5 (±9.0) .93∗
Baseline BCVA LogMAR (±SD) 0.46 (±0.31) 0.64 (±0.39) 0.55 (±0.36) .053∗
Baseline CRT (±SD) µm 414 (±191) 374 (±109) 395 (±158) .34∗
Baseline GLD (±SD) µm 4558 (±1712) 3530 (±996) 4138 (±1479) .0068∗
Subretinal hemorrhage (>1 disc) 9 (28%) 5 (18%) 14 (23%) .34†
BMI 22.2 (±2.5) 21.2 (±2.5) 22.4 (±2.9) .56∗
Present or ever smoker 20 (63%) 21 (75%) 41 (68%) .45†
Hypertension 14 (44%) 10 (36%) 24 (40%) .71†
Diabetes mellitus 5 (16%) 6 (21%) 11 (18%) .81†
GLD: greatest linear dimension, BCVA: best-corrected visual acuity, CRT: central retinal thickness,and BMI: body mass index. ∗Unpaired t-test; †×2t e s t .
Table 2: Changes in the BCVA and CRT from baseline after IVR treatment in tAMD and PCV patients.






PCV −0.0086 0.00 (−0.090–0.00) .38∗ −0.011 0.00 (−0.12–0.030) .55∗
tAMD −0.093 0.00 (−0.17–0.00) .0084∗ −0.19 −0.12 (−0.30–0.00) .00080∗
P value .42† .0045†
CRT
PCV −118 −111 (−166–−32) <.0001∗ −173 −130 (−212–−63) <.0001∗
tAMD −104 −84 (−147–−57) <.0001∗ −129 −97 (−182–−64) <.0001∗
P value .80† .58†
BCVA: best-corrected visual acuity(LogMAR); CRT: central retinal thickness.
∗Wilcoxon’s signed-rank test (comparison to baseline).
†Mann-Whitney U test (comparison between PCV and tAMD at the same month).
Table 3: Changes in the BCVA from baseline after IVR treatment in the patients having subretinal hemorrhage before treatment.
1m o n t h( n = 60) P value 3 months (n = 60) P value




>1D A(n = 14) 0.0053 0.00 (−0.079–0.18) .57∗ −0.040 0.00 (−0.097–0.020) 1.00∗
￿1D A(n = 46) −0.064 −0.023 (−0.12–0.00) .0008∗ −0.11 −0.097 (−0.18–0.00) .0002∗
P value .065† .10†
BCVA: best-corrected visual acuity(LogMAR); DA: disc area.
∗Wilcoxon’s signed-rank test (comparison to baseline).
†Mann-Whitney U test (comparison between PCV and tAMD at the same month).
complications were detected during the follow-up term in
the present study.
4.Discussion
We compared the early response to IVR in diﬀerent pheno-
types of exudative AMD and demonstrated that the visual
improvement was signiﬁcantly greater in tAMD subjects
than in PCV. In other words, the phenotype of exudative
AMD was a signiﬁcant prognostic factor for the visual acuity
after IVR.
Currently, IVR is the leading therapy for exudative AMD
[15, 16], pathological myopia [17, 18], idiopathic CNV [19],
and many secondary CNVs [19, 20]. Previous randomized
studies with large populations have demonstrated the eﬃ-
cacy of IVR for exudative AMD with classic and occult CNV
lesions found using FA in Caucasian populations [21, 22].












































Figure 2: Changesin central retinal thickness(CRT) fortAMD and
PCVpatientsafterintravitreal ranibizumab.Diamondswithdashed
lines: tAMD; squares with solid lines: PCV. Values represent means
± SEM.
Table 4: Multiple regression analysis of preoperative variables with




(female = 0, male = 1)
Smoking −0.14 .30
(nonsmoker = 0, present and
ever smokers = 1)
Hypertension 0.11 .41
(no history = 0, present = 1)
Diabetes Mellitus 0.041 .76
(no history = 0, present = 1)
Phenotype −0.38 .013
(PCV = 0, tAMD = 1)
Baseline BCVA (LogMAR) −0.36 .026
Baseline CRT (µm) 0.11 .40
Subretinal hemorrhage (
￿1D A
= 0, >1D A= 1) 0.21 .11
Greatest linear dimension (µm) 0.15 .27
BCVA: best-corrected visual acuity, IVR: intravitreous ranibizumab, CRT:
central retinal thickness,and DA: disc area. r: partial correlation coeﬃcient.
whichlikelyincludesanumberofPCVpatients,didnotshow
as good response to intravitreal bevacizumab as Caucasian
subjects [5, 8, 23]. PCV is known to have some diﬀerent
characteristics as compared with tAMD, such as orange-red
protrusions at the posterior pole of the retina and distinct
formsofchoroidalvascularabnormalities,includingvascular
networks of choroidal origin with polypoidal lesions at
their border visualized by ICG [11, 13]. PCV often shows
spontaneous regression in its natural course, but on the
otherhand, itoften causes severe hemorrhagic and exudative
changes that result in a poor visual prognosis [12, 13]. PCV
is known to have a better response to photodynamic therapy
(PDT) than tAMD, but the reason for this is not understood
[24, 25]. Since PCV accounts for 54.7% of patients with
neovascular AMD in the Japanese population [6] and 22.3%
in the Chinese population [26], it is important to determine
if there are some diﬀerences in the eﬃcacy of anti-VEGF
therapy against PCV and tAMD to choose the correct
interventions for neovascular AMD in Asian populations.
Our results showed a signiﬁcant increase in the mean
BCVA in patients with tAMD and a modest improvement
in those with PCV. It was interesting that PCV patients
showed poorer improvements in their BCVA than tAMD
patients, although both phenotypes showed similar signiﬁ-
cant improvements in their CRT during 3 months after the
initial IVR. A previous report showed a decrease in macular
edema after three monthly bevacizumab injections in PCV
cases [27]. Similarly, macular edema evaluated by CRT
measurements was improved in four out of ﬁve eyes with
PCV (80%) in the PEARL study. However, the improvement
in the BCVA was less than that in the ANCHOR trial or
the MARINA trial, although the reasons are unknown [28].
We hypothesized that there might be factors other than
macular edema which inﬂuence the visual acuity in tAMD
and PCV cases diﬀerently. Although the mean baseline GLD
was signiﬁcantly greater in the PCV group than in the
tAMD group in the present study, the results of multivariate
regression analysisrevealedthatthelesionphenotype(tAMD
or PCV) was the independent prognostic factor for the 3-
month visual outcome after IVR. As described in previous
reports, the baseline BCVA is another factor that may
inﬂuence the early eﬀects of IVR. We found that a reduction
of BCVA improvement after the initial 3 monthly IVR was
predominantly due to the recurrence of the lesions, which
suggested that more frequent IVRs were required during the
follow-upperiod.However,greaterimprovementofBCVAin
the ﬁrst 3 months indicated better visual prognosis in tAMD
than PCV treated by IVR.
Currently, there are some discrepancies in the literature
regarding the eﬀects of IVR against PCV. Some studies
reported that the polypoidal lesions of PCV were barely
resolved by anti-VEGF monotherapy, which might explain
the limited eﬃcacy of IVR on PCV [8, 9]. However, other
reports suggested that the disappearance of the polypoidal
lesions occurred at a high rate in the PCV cases with
anti-VEGF monotherapy [27, 29, 30]. Although the PCV
cases showed a lower response (increased BCVA) to IVR
than the tAMD patients during the ﬁrst 3 months in
the present study, several studies reported a signiﬁcant
improvement of the visual acuity in PCV patients using
IVR without any comparison to that in tAMD patients
[29, 30]. Moreover, several reports have shown diﬀerent
outcomes for photodynamic therapy (PDT) between tAMD
and PCV [24, 25]. In those reports, signiﬁcantly better
visual outcomes in PCV than in tAMD were demonstrated.
Hence, it is important to evaluate the long-term results
of IVR with a large number of subjects to determine the
eﬃcacy and durability of this therapy, particularly in PCV
patients. Taken together, further investigation will be needed
to determine the correct indications of IVR for exudative
AMD.Journal of Ophthalmology 5
5.Conclusion
IVR is an eﬀective therapy for prompt increases in the BCVA
in tAMD patients, although this eﬀect might be limited in
PCV patients in a Japanese population.
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